What is GLP-1 generic distribution in India?

GLP-1 drugs (semaglutide, tirzepatide) for weight loss and diabetes are now generic post-patent expiry. A distribution business buys from manufacturers and supplies chemists, clinics, and hospitals across states. India's obesity market is 150+ million potential patients; current penetration is <5%, making this a high-growth segment.

How much does it cost to start GLP-1 distribution in India?

₹4–7 crore for MVP: ₹2–2.5 crore for cold-chain warehouses (3 hubs), ₹0.8–1.2 crore for fleet and logistics, ₹0.5–1 crore for regulatory licenses and tech platform, ₹0.7–1.3 crore working capital for inventory and chemist payments.

Is GLP-1 distribution profitable in India?

Yes. Distributors earn 8–12% margin on ₹2,000–3,000 crore annual turnover = ₹160–360 crore gross revenue. Net margins typically 6–8% after logistics, compliance, and shrinkage = ₹120–240 crore potential EBITDA at scale (3–4 years). First-year breakeven is achievable at ₹100–150 crore turnover.

What regulations apply to GLP-1 distribution in India?

Drugs & Cosmetics Act 1940 (state pharma license); GST 5% on pharma wholesale; CDSCO approval of source manufacturers; cold-chain certification (FSSAI or state health dept); pharmacy council registration per state; insurance tie-up compliance if offering reimbursement facilitation. Licenses take 6–8 weeks.

GLP-1 Generic Drug Distribution India 2026 — Business Guide

Q: How much does it cost to start GLP-1 distribution in India?

₹4–7 crore for MVP: ₹2–2.5 crore for cold-chain warehouses (3 hubs), ₹0.8–1.2 crore for fleet and logistics, ₹0.5–1 crore for regulatory licenses and tech platform, ₹0.7–1.3 crore working capital for inventory and chemist payments.

Q: Is GLP-1 distribution profitable in India?

Yes. Distributors earn 8–12% margin on ₹2,000–3,000 crore annual turnover = ₹160–360 crore gross revenue. Net margins typically 6–8% after logistics, compliance, and shrinkage = ₹120–240 crore potential EBITDA at scale (3–4 years). First-year breakeven is achievable at ₹100–150 crore turnover.

Q: What regulations apply to GLP-1 distribution in India?

Drugs & Cosmetics Act 1940 (state pharma license); GST 5% on pharma wholesale; CDSCO approval of source manufacturers; cold-chain certification (FSSAI or state health dept); pharmacy council registration per state; insurance tie-up compliance if offering reimbursement facilitation. Licenses take 6–8 weeks.

AI SummaryGLP-1 generic distribution in India represents a ₹8,500–12,000 crore opportunity by 2026 as patent expiries slash drug costs by 90%. With 150+ million obese and diabetic Indians and current penetration below 5%, the market is primed for mass-market distribution. Entrepreneurs with pharma supply-chain expertise and ₹4–7 crore capital can capture 8–12% wholesale margins by building cold-chain networks across tier-2/3 cities and partnering with endocrinologists and chemists. Regulatory compliance (pharma license, GST, CDSCO approval) is straightforward and timeline is 6–8 weeks.